HOME >> MEDICINE >> NEWS
Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

CD40L Moved Forward Based On Outcomes Of Multi-Dose Safety Trial

SEATTLE - Immunex Corporation (Nasdaq: IMNX) announced today that it has launched a Phase II trial of the investigational agent CD40 Ligand (CD40L) in the most common form of kidney cancer, renal cell carcinoma. The company is continuing the development of CD40L based on results of a multi-dose Phase I trial of the drug in advanced cancer patients.

The Phase I study, which evaluated escalating doses of CD40L in patients with recurrent solid tumors and lymphoma, has been completed and the objectives of the study were met. The results of this multi-dose study will be presented at a future medical meeting. Several pre-clinical studies on the anti-tumor effect of CD40L will be presented next week at the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO). In these studies, conducted in both mice and fresh human tumor samples, CD40L inhibited tumor growth in multiple solid tumor types, such as breast, lung, ovarian and colon.

"Based on the results of these safety trials, Immunex is moving forward with a Phase II trial of CD40L in metastatic renal cell carcinoma," said Ann Hayes, M.D., senior vice president, medical development, Immunex. "Patients with this disease currently have limited treatment options. Treatment with CD40L represents a novel approach to treating cancer, by potentially having a direct effect on tumor cells and by stimulating the immune system to recognize and seek out cancer cells for destruction."

The study, being conducted in three cancer treatment centers across the United States, will evaluate the safety and efficacy of the drug in metastatic renal cell carcinoma.

Approximately 30,000 new cases of kidney cancer will be diagnosed this year in the United States and about 11,900 people will die from this disease. It is the 8th most common cancer in men and the 10th most common in women. Ren
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
14-May-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
4. Advances in plasma physics at Annual APS Meeting
5. Advances in plasma physics at Annual APS Meeting
6. Advances in understanding brain circuits responsible for tics in Tourettes shed light on disorder
7. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
8. Advances emerging in hepatitis management
9. Advances in prevention and treatment research hold promise for pipeline
10. Advances in MRI imaging may lead to new standards for faster diagnosis of multiple sclerosis
11. Peanut Allergy: Major Advances in Treatment and Education

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2018)... (PRWEB) , ... August 31, 2018 , ... ... its neuroimaging capabilities with the addition of an MRI Simulator. In the MRI ... scan including sounds. By engaging in this mock scan experience, research participants become ...
(Date:8/31/2018)... Calif. (PRWEB) , ... August 31, 2018 , ... Nitro ... at SeaLegs at the Beach – an action sports gathering to celebrate the life ... Crew. The event raised money for Erik’s wife, Annika and their two small children, ...
(Date:8/31/2018)... ... August 31, 2018 , ... Saturday, September 1st, 2018, Team Fastrax™ will perform ... Cyclones season opener game. At 7pm, the Cyclones will kick off against the South ... play, Team Fastrax™ will jump in with their majestic 2,000 sq. ft. American Flag, ...
(Date:8/29/2018)... PHILADELPHIA (PRWEB) , ... August 29, 2018 , ... ... Pennsylvania region announced that they will be relocating two of their offices ... location in Mechanicsburg, PA, just a few miles away, located on the campus of ...
(Date:8/29/2018)... ST. LOUIS, Mo. (PRWEB) , ... August 29, ... ... infographic entitled “Smoking vs. Vaping: What You Need to Know” to provide information ... infographic , The Vape Mall lays out the similarities, and, more importantly, differences ...
Breaking Medicine News(10 mins):
(Date:9/15/2018)... N.C. (PRWEB) , ... September 14, 2018 , ... "As ... on the map thanks to Hurricane Florence. I am planning this Women of Influence ... living out of a suitcase and knowing I have to hold onto my faith ...
(Date:9/13/2018)... ... September 13, 2018 , ... NCPDP announced today that ... ensure correct implementation of the NCPDP SCRIPT Standard Version 2017071 ahead of the ... transactions identified by the industry as vital enhancements in improving patient safety, clinical ...
(Date:9/12/2018)... ... September 12, 2018 , ... Surgical Theater will be exhibiting ... September 19-22. The IT + Revenue Cycle Conference provides Surgical Theater with a ... use of Precision Virtual Reality™ medical visualization platform. This 360VR technology allows patients ...
Breaking Medicine Technology:
Cached News: